Entinostat: Phase Ib/II started

Syndax and Merck began the open-label, dose-escalation, U.S. Phase Ib/II ENCORE 601/KEYNOTE 142 trial of 3, 5 and 10 mg oral entinostat weekly with Merck’s IV Keytruda pembrolizumab in up to 178 patients. The Phase Ib portion will evaluate the combination in NSCLC patients and the Phase II portion will test the combination in NSCLC or melanoma patients. Syndax designated the trial as ENCORE 601; Merck designated it as KEYNOTE 142. In March, the companies partnered to conduct the trial (see BioCentury, April 6). ...